Skip to content

Aspirin and heparin in recurrent pregnancy loss treatment

Effectiveness of aspirin in compare with heparin plus aspirin in recurrent pregnancy loss treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013102315123N1
Enrollment
252
Registered
2013-12-24
Start date
2010-10-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent pregnancy loss. Spontaneous abortion

Interventions

Intervention 1: Intervention: aspirin, 80mg, daily, two month before pregnancy and after pregnancy until 36 weeks of gestation, plus heparin, 5000unit twice a day after pregnancy until 4 weeks afte
Treatment - Drugs
Intervention: aspirin, 80mg, daily, two month before pregnancy and after pregnancy until 36 weeks of gestation, plus heparin, 5000unit twice a day after pregnancy until 4 weeks after delivery
Control: aspirin orally, 80mg, daily for two month before pregnancy and afte pregnancy until 36 weeks of gestation

Sponsors

Research and Clinical Center for Infertility,Yazd, Iran
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: unexplained recurrent pregnancy loss; women with thrombophilia exclusion criteria: abnormal karyotypes of each partner; uterine; cervical anatomical disorders on pelvic ultrasonography; hysteroscopy; abnormal ovaries function; abnormal endocrine tests; and antiphospholipid syndrome

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pregnancy after 20 weeks. Timepoint: after 20 weeks. Method of measurement: Sonography.

Secondary

MeasureTime frame
Live-birth rates. Timepoint: 2 weeks after intervention. Method of measurement: mesearment of blood beta hCG.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNasrin Ghasemi

Research and Clinical Center for Infertility, Yazd, Iran

ghasemi@ssu.ac.ir+98 35 1824 8122

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026